Indications for: EMTRIVA ORAL SOLUTION
HIV-1 infection, in combination with other antiretroviral agents.
≥18yrs: 240mg (24mL) once daily. Renal impairment: (CrCl 30–49mL/min): 120mg (12mL) once daily; (CrCl 15–29mL/min): 80mg (8mL) once daily; (CrCl <15mL/min or dialysis): 60mg (6mL) once daily.
<3mos: 3mg/kg once daily. 3mos–17yrs: 6mg/kg [max 240mg (24mL)] once daily. >33kg: may use cap form. Renal impairment: reduce dose or prolong dosing interval (see full labeling).
Posttreatment exacerbation of hepatitis B.
EMTRIVA ORAL SOLUTION Warnings/Precautions:
Not for treating chronic HBV infection; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Renal impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.
EMTRIVA ORAL SOLUTION Classification:
Nucleoside analogue (reverse transcriptase inhibitor).
EMTRIVA ORAL SOLUTION Interactions:
Avoid concomitant drugs that contain emtricitabine or lamivudine (eg, fixed dose combination products).
Headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, rhinitis; new onset or worsening renal impairment, immune reconstitution syndrome; also children: skin hyperpigmentation.
Register pregnant patients exposed to emtricitabine by calling (800) 258-4263.